Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer

Human Pathology

Volumn 41, Issue 1, 2010, Pages 48-58

  Fu, De Yuan ^a,b   Wang, Zhi Min ^c   Wang, Bei Lan ^c   Chen, Li ^a   Yang, Wen Tao ^a   Shen, Zhen Zhou ^a   Huang, Wei ^c   Shao, Zhi Ming ^a  

^a Cancer Hospital   (China)

^b NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

^c CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Breast cancer; DNA methylation; EphA5; Epigenetic inactivation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; EPHRIN RECEPTOR A5; MESSENGER RNA; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; CANCER CELL; CANCER GRADING; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE INACTIVATION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROMOTER REGION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BASE SEQUENCE; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; RECEPTOR, EPHA5; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 71249098177     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.06.007     Document Type: Article

References (33)

1. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 (2003) 2042-2054
2. Das P.M., and Singal R. DNA methylation and cancer. J Clin Oncol 22 (2004) 4632-4642
3. Szyf M., Pakneshan P., and Rabbani S.A. DNA methylation and breast cancer. Biochem Pharmacol 68 (2004) 1187-1197
4. Kullander K., and Klein R. Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol 3 (2002) 475-486
5. Holmberg J., Clarke D.L., and Frisén J. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 408 (2000) 203-206
6. Merlos-Suárez A., and Batlle E. Eph-ephrin signalling in adult tissues and cancer. Curr Opin Cell Biol 20 (2008) 194-200
7. Liu W., Ahmad S.A., Jung Y.D., et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 94 (2002) 934-939
8. Kinch M.S., Moore M.B., and Harpole Jr. D.H. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9 (2003) 613-618
9. Walker-Daniels J., Coffman K., Azimi M., et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41 (1999) 275-280
10. Andres A.C., Reid H.H., Zürcher G., et al. Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene 9 (1994) 1461-1467
11. Noren N.K., Foos G., Hauser C.A., et al. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8 (2006) 815-825
12. Fang W.B., Brantley-Sieders D.M., Parker M.A., et al. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24 (2005) 7859-7868
13. Ireton R.C., and Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 5 (2005) 149-157
14. Fox B.P., and Kandpal R.P. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun 318 (2004) 882-892
15. Brantley-Sieders D.M., Zhuang G., Hicks D., et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118 (2008) 64-78
16. Lu M., Miller K.D., Gokmen-Polar Y., et al. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res 63 (2003) 3425-3429
17. Dottori M., Down M., Hüttmann A., et al. Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 94 (1999) 2477-2486
18. Wang J., Kataoka H., Suzuki M., et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24 (2005) 5637-5647
19. Wang J., Li G., Ma H., Bao Y., et al. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum Pathol 38 (2007) 1649-1656
20. Dawson D.W., Hong J.S., Shen R.R., et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 26 (2007) 4243-4252
21. Fox B.P., and Kandpal R.P. Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR. Biochem Biophys Res Commun 340 (2006) 268-276
22. Yue Y., Chen Z.Y., Gale N.W., et al. Mistargeting hippocampal axons by expression of a truncated Eph receptor. Proc Natl Acad Sci U S A 99 (2002) 10777-10782
23. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
24. Molino A., Micciolo R., Turazza M., et al. Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 34 (1995) 221-228
25. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
26. Feltus F.A., Lee E.K., Costello J.F., et al. Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A 100 (2003) 12253-12258
27. Matros E., Wang Z.C., Lodeiro G., et al. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 91 (2005) 179-186
28. Holst C.R., Nuovo G.J., Esteller M., et al. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 63 (2003) 1596-1601
29. Nass S.J., Herman J.G., Gabrielson E., et al. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 60 (2000) 4346-4348
30. Ottaviano Y.L., Issa J.P., Parl F.F., et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54 (1994) 2552-2555
31. Fackler M.J., McVeigh M., Evron E., et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107 (2003) 970-975
32. Carter C.L., Allen C., and Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63 (1989) 181-187
33. Lehmann U., Langer F., Feist H., et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 160 (2002) 605-612